Generic Name:
Brentuximab vedotin
Project Status:
Complete
Therapeutic Area:
Systemic Anaplastic Large Cell Lymphoma
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0021-000
NOC Date:
Details
Strength:
50mg/vial
Tumour Type:
Lymphoma
Indications:
Systemic Anaplastic Large Cell Lymphoma
Funding Request:
For second-line treatment of sALCL patients - i.e. after failure of at least one prior multi-agent chemotherapy regimen
Review Status:
Complete
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
Time required for the submitter to provide additional economic information has impacted the review timeline.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
Time required for the submitter to provide additional economic information has impacted the review timeline.
Funding Request:
For second-line treatment of sALCL patients - i.e. after failure of at least one prior multi-agent chemotherapy regimen
pERC Meeting:
Final Recommendation Issued: